# FORM 13

## NOTICE OF AMENDMENT OF WARRANT TERMS

Name of Listed Issuer: **MARAPHARM VENTURES INC.** (the "Issuer").

Trading Symbol: **MDM**

Date: **March 16, 2016**

Date of Press Release announcing amendment: **March 16, 2016**

Closing price of underlying shares on the day prior to the announcement **$0.25**

Closing price of underlying shares at the time of issuance **$0.37**

**1. Current terms of warrants to be amended:**

| Date Issued | Issue Price | Exercise Price | Market Price of underlying shares | Number of Warrants | Expiry Date | Percentage of Warrant class held by Insiders |
|---|---|---|---|---|---|---|
| Sept 25 2015 | $0.37 | $0.37 | $0.37 | 1,100,000 | March 25, 2016 | 0% |
| | | | | | | |

Pursuant to Policy 6, Section 7.4, Amendments are permitted provided that:

**a)** The warrants are not listed for trading;

**b)** The exercise price is higher than the current market price;

**c)** No warrants have been exercised in the last 6 months;

**d)** At least 10 trading days remain before expiry.

## 2. Amendment(s)

**a)** Extension – amended expiry date: __**March 25, 2017**

*The term of a warrant may not extend past the date that would have been allowed on the date of issuance.*

**b)** Repricing – amended exercise price:____**N/A**_____

## 3. Amended terms of warrants:

| Date Issued | Issue Price | Exercise Price | Market Price of underlying shares | Number of Amended Warrants | Expiry Date | Percentage of Warrant class held by Insiders |
|---|---|---|---|---|---|---|
| Sept 25 2016 | $0.37 | $0.37 | $0.37 | 1,100,000 | March 25, 2017 | 0% |
| | | | | | | |

## 4. Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.

3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in Policy 1).

4. All of the information in this Form 13 Notice of Amendment of Warrant Terms is true.

Dated **March 16, 2016**

Les Kjosness
Name of Director or Senior Officer

*" Les Kjosness"*
Signature

President
Official Capacity